Independent biostatisticians recommend continuing PALISADE-2 without any changes after conducting interim analysis of 140 completed subjects Topline data for PALISADE-2 trial expected in the first half of 2023 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 8, 2022-- Vistagen Therapeutics, Inc.

Evaluation of PALISADE-1 continues and interim analysis of PALISADE-2 begins Preliminary data from nearly 200 subjects in the PALISADE open label safety study suggest that continued as-needed use of PH94B has potential to achieve cumulative functional improvement in the severity of social anxiety

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 9, 2022-- VistaGen Therapeutics, Inc . (NASDAQ: VTGN) a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today

PH94B for Acute Treatment of Social Anxiety Disorder Did Not Meet Primary Endpoint PH94B Showed a Favorable Safety and Tolerability Profile among Study Participants that was Consistent with Prior Clinical Trial Results SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul.

Leaders will explore public and private sector solutions to social challenges SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 12, 2022-- VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 7, 2022-- VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen), a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and

Completed last patient out milestone for PALISADE-1 Phase 3 clinical trial of PH94B in social anxiety disorder (SAD). Topline results for PALISADE-1 anticipated mid-2022. PALISADE-2 on track for topline readout in late 2022. Received FDA consensus that data from nonclinical and clinical studies of

PALISADE Phase 3 Program focused on PH94B’s potential as a rapid-onset, acute treatment of anxiety in adults with social anxiety disorder FDA Fast Track designation granted Topline results anticipated mid-2022 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun.

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 17, 2022-- VistaGen Therapeutics, Inc. (NASDAQ: VTGN) a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other CNS

SOUTH SAN FRANCISCO --(BUSINESS WIRE)--Jun. 2, 2022-- VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen), a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other